1,424 results on '"Blank, Christian"'
Search Results
2. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
3. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
4. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
5. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
6. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
7. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
8. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
9. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
10. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
11. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
12. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
13. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
14. Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
15. The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
16. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
17. Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform
18. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
19. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
20. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
21. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
22. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
23. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
24. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
25. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery
26. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry
27. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
28. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
29. B cells and tertiary lymphoid structures promote immunotherapy response
30. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
31. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
32. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
33. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
34. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
35. Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma
36. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
37. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
38. The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021
39. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
40. Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
41. The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.
42. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
43. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
44. Adjuvant treatment for melanoma in clinical practice – Trial versus reality
45. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
46. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
47. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
48. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
49. Metabolic profiles of regulatory T cells in the tumour microenvironment
50. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.